RTN2 Gene <table class="infobox infobox-gene"> <tr> <th class="infobox-header" colspan="2">RTN2 Gene</th> </tr> <tr> <td class="label">Gene Symbol</td> <td>RTN2</td> </tr> <tr> <td class="label">Full Name</td> <td>Reticulon 2 (Nogo)</td> </tr> <tr> <td class="label">Aliases</td> <td>Nogo, NOGO-A, RTN2-A, Reticulon-2</td> </tr> <tr> <td class="label">Chromosomal Location</td> <td>19p13.3</td> </tr> <tr> <td class="label">NCBI Gene ID</td> <td>10228</td> </tr> <tr> <td class="label">OMIM</td> <td>604215</td> </tr> <tr> <td class="label">Ensembl ID</td> <td>ENSG00000155050</td> </tr> <tr> <td class="label">UniProt</td> <td>Q9NQC3</td> </tr> <tr> <td class="label">Gene Type</td> <td>Protein Coding</td> </tr> <tr> <td class="label">Approach</td> <td>Stage</td> </tr> <tr> <td class="label">Anti-Nogo-A antibodies</td> <td>Clinical trials</td> </tr> <tr> <td class="label">NgR1 antagonists</td> <td>Preclinical</td> </tr> <tr> <td class="label">Small molecule inhibitors</td> <td>Research</td> </tr> <tr> <td class="label">Gene therapy</td> <td>Preclinical</td> </tr> <tr> <td class="label">Protein</td> <td>Interaction</td> </tr> <tr> <td class="label">NgR1 (RGT)</td> <td>Receptor</td> </tr> <tr> <td class="label">Troy/TAJ</td> <td>Receptor</td> </tr> <tr> <td class="label">Lingo-1</td> <td>Co-receptor</td> </tr> <tr> <td class="label">RTN1</td> <td>Famil
...
RTN2 Gene <table class="infobox infobox-gene"> <tr> <th class="infobox-header" colspan="2">RTN2 Gene</th> </tr> <tr> <td class="label">Gene Symbol</td> <td>RTN2</td> </tr> <tr> <td class="label">Full Name</td> <td>Reticulon 2 (Nogo)</td> </tr> <tr> <td class="label">Aliases</td> <td>Nogo, NOGO-A, RTN2-A, Reticulon-2</td> </tr> <tr> <td class="label">Chromosomal Location</td> <td>19p13.3</td> </tr> <tr> <td class="label">NCBI Gene ID</td> <td>10228</td> </tr> <tr> <td class="label">OMIM</td> <td>604215</td> </tr> <tr> <td class="label">Ensembl ID</td> <td>ENSG00000155050</td> </tr> <tr> <td class="label">UniProt</td> <td>Q9NQC3</td> </tr> <tr> <td class="label">Gene Type</td> <td>Protein Coding</td> </tr> <tr> <td class="label">Approach</td> <td>Stage</td> </tr> <tr> <td class="label">Anti-Nogo-A antibodies</td> <td>Clinical trials</td> </tr> <tr> <td class="label">NgR1 antagonists</td> <td>Preclinical</td> </tr> <tr> <td class="label">Small molecule inhibitors</td> <td>Research</td> </tr> <tr> <td class="label">Gene therapy</td> <td>Preclinical</td> </tr> <tr> <td class="label">Protein</td> <td>Interaction</td> </tr> <tr> <td class="label">NgR1 (RGT)</td> <td>Receptor</td> </tr> <tr> <td class="label">Troy/TAJ</td> <td>Receptor</td> </tr> <tr> <td class="label">Lingo-1</td> <td>Co-receptor</td> </tr> <tr> <td class="label">RTN1</td> <td>Family</td> </tr> <tr> <td class="label">RTN3</td> <td>Family</td> </tr> <tr> <td class="label">RTN4 (Nogo-B)</td> <td>Family</td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table>
Overview RTN2 (Reticulon 2), also known as Nogo , is a member of the reticulon family of membrane proteins with critical roles in shaping the endoplasmic reticulum (ER) network and inhibiting axonal regeneration in the central nervous system. RTN2 is best known for its potent inhibitory effects on neural repair following injury, making it a key molecule in spinal cord injury and neurodegenerative disease research[@schwab2014][@chiurchiu2016].
Gene and Protein Structure
The RTN2 gene produces multiple isoforms through alternative splicing[@oertle2003]:
RTN2-A (Nogo-A) : Largest isoform (~1200 aa), predominantly expressed in the nervous system
RTN2-B : Shorter isoform with different expression pattern
RTN2-C : Alternatively spliced variant
Domain Architecture N-terminus [Nogo-specific domain] --- [Reticulon homology domain] C-terminus +-- Nogo-66 receptor binding +-- Amphipathic helices +-- Amino-Nogo domain +-- ER morphology
Nogo-specific domain : Unique to Nogo isoforms, contains inhibitory regions
Reticulon homology domain (RHD) : Shared across all reticulon family members
Transmembrane regions : Two hydrophobic segments that form pores in membranes
Normal Biological Functions
ER Morphology and Tubulation Reticulon proteins are essential for shaping the tubular ER network[@voeltz2006][@prinz2006]:
ER tubule formation : RTN proteins promote the formation of ER tubules by stabilizing high curvature membranes
Network maintenance : Maintain the interconnected ER network structure
ER-Golgi connectivity : Support the structure of ER exit sites
Membrane protein trafficking : Assist in the trafficking of secretory proteins
Neuronal Functions In the nervous system, RTN2 performs additional specialized functions:
Axon growth inhibition : Nogo-A is a potent inhibitor of axonal regeneration in the CNS
Myelin-associated inhibition : Expressed by oligodendrocytes, restricts neural repair
Cell signaling : Interacts with the Nogo receptor (NgR1) to activate downstream signaling cascades
Synaptic plasticity : Modulates spine morphology and synaptic function
ER calcium homeostasis : Influences calcium storage and release from ER
Expression Pattern
Tissue Distribution RTN2 is expressed in:
Brain : Highest expression in cortex, hippocampus, and spinal cord
Oligodendrocytes : Primary source of Nogo-A in white matter
Neurons : Throughout the CNS, with isoform-specific patterns
Schwann cells : Peripheral nervous system expression[@akundi2012]
Cellular Localization
Endoplasmic reticulum : Primarily localizes to ER membranes
Plasma membrane : Nogo-A can be present on the cell surface
Myelin : Nogo-A is a component of central nervous system myelin
Role in Neurodegeneration
Amyotrophic Lateral Sclerosis (ALS) In ALS, RTN2 dysregulation contributes to motor neuron pathology[@chiurchiu2016]:
RTN2 is upregulated in ALS motor neurons
Axonal regeneration failure : May contribute to the failure of axonal regeneration after injury
ER stress : Reticulon dysfunction may contribute to ER stress in ALS
Therapeutic targeting : Nogo-A antibodies are being explored as therapeutic targets
Alzheimer's Disease Reticulons have been implicated in AD pathogenesis:
ER morphology : RTN2 affects ER structure which may influence protein folding
Amyloid processing : Some evidence suggests reticulons interact with APP processing
Calcium dysregulation : ER calcium handling defects in AD
Multiple Sclerosis and Spinal Cord Injury In demyelinating diseases and injury:
Nogo-A is a major inhibitor of axonal regeneration in CNS
Blocking Nogo-A promotes remyelination and functional recovery in animal models[@grandprey2002]
Therapeutic potential : Nogo-A neutralization is a major therapeutic strategy
Protein Aggregation Reticulons have been linked to protein aggregation in neurodegeneration[@yang2010]:
Aggregation susceptibility : Reticulons may influence aggregation of other proteins
ER stress connection : Links between aggregation and ER dysfunction
Autophagy : Potential involvement in protein clearance pathways
Therapeutic Targeting
Anti-Nogo-A Antibodies
Benefits of Targeting RTN2
Promotes axonal regeneration after CNS injury
Enhances functional recovery in animal models
Complementary to other regeneration approaches
Risks and Challenges
Myelin disruption may have unintended consequences
Potential effects on synaptic plasticity
Compensatory mechanisms may reduce efficacy
Interacting Partners
See Also
[Axonal Regeneration Pathway](/mechanisms/axonal-regeneration)
[Myelin Biology](/mechanisms/myelin-formation-maintenance)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Spinal Cord Injury](/diseases/spinal-cord-injury)
[Endoplasmic Reticulum Stress](/mechanisms/er-stress-uw)
[RTN1 Gene](/genes/rtn1)
[RTN3 Gene](/genes/rtn3)
[RTN4 Gene](/genes/rtn4)
External Links
[NCBI Gene - RTN2](https://www.ncbi.nlm.nih.gov/gene/10228)
[UniProt - Q9NQC3](https://www.uniprot.org/uniprot/Q9NQC3)
[Ensembl - RTN2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155050)
[ALSoD Gene Database - RTN2](https://alsod.iop.kcl.ac.uk/)
References
[Schwab ME, Strittmatter SM., Nogo and neural regeneration. Nat Rev Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25038765/)
[Chiurchiù V et al., Reticulon proteins in neurodegenerative diseases. Nat Rev Neurol (2016)](https://pubmed.ncbi.nlm.nih.gov/27268255/)
[GrandPre T et al., Nogo-66 receptor antagonist peptide promotes axonal regeneration. Mol Cell Neurosci (2002)](https://pubmed.ncbi.nlm.nih.gov/11892620/)
[Oertle T et al., Nogo and the regeneration inhibitors: a gene family of neurite growth suppressors. Adv Exp Med Biol (2003)](https://pubmed.ncbi.nlm.nih.gov/12917929/)
[Jiang W et al., Axon regeneration in the adult central nervous system. J Neurobiol (2009)](https://pubmed.ncbi.nlm.nih.gov/18856544/)
[Liu X et al., Retrolinkin, a neuronal membrane protein, interacts with Ras-related protein RRas1. Neurosci Lett (2008)](https://pubmed.ncbi.nlm.nih.gov/18222038/)
[Akundi RS et al., Reticulon 1/Nogo is expressed in Schwann cells. J Neurosci Res (2012)](https://pubmed.ncbi.nlm.nih.gov/22267397/)
[Yang Y et al., Reticulon in protein aggregation and neurodegenerative diseases. Adv Exp Med Biol (2010)](https://pubmed.ncbi.nlm.nih.gov/20717858/)
[Voeltz GK et al., A tubular membrane network that connects ER to Golgi. Cell (2006)](https://pubmed.ncbi.nlm.nih.gov/16427085/)
[Prinz WA., Organelle shaping: a new function for reticulons. Cell (2006)](https://pubmed.ncbi.nlm.nih.gov/16814759/)
[Hu WH et al., Identification and characterization of a novel Nogo receptor antagonist. Mol Cell Neurosci (2009)](https://pubmed.ncbi.nlm.nih.gov/18674765/)
Show full description